Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy
Abstract Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system. Furthermore, although 17β-estradiol (E2) is a potential anti-hypertrophic drug, it has severe non-specif...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-03-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12951-018-0360-3 |
| _version_ | 1828353329296572416 |
|---|---|
| author | Xueli Zhao Wen Luo Jing Hu Lei Zuo Jing Wang Rui Hu Bo Wang Lei Xu Jing Li Meng Wu Pan Li Liwen Liu |
| author_facet | Xueli Zhao Wen Luo Jing Hu Lei Zuo Jing Wang Rui Hu Bo Wang Lei Xu Jing Li Meng Wu Pan Li Liwen Liu |
| author_sort | Xueli Zhao |
| collection | DOAJ |
| description | Abstract Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system. Furthermore, although 17β-estradiol (E2) is a potential anti-hypertrophic drug, it has severe non-specific adverse effects in various organs. Therefore, we have developed cardiomyocyte-targeted theranostic nanoprobes to achieve concurrent targeted imaging and treatment of cardiac hypertrophy. Results We had successfully synthesized E2-loaded, primary cardiomyocyte (PCM) specific peptide-conjugated nanoprobes with perfluorocarbon (PFP) as a core (PCM-E2/PFPs) and demonstrated their stability and homogeneity. In vitro and in vivo studies confirmed that when exposed to low-intensity focused ultrasound (LIFU), these versatile PCM-E2/PFPs can be used as an amplifiable imaging contrast agent. Furthermore, the significantly accelerated release of E2 enhanced the therapeutic efficacy of the drug and prevented systemic side effects. PCM-E2/PFPs + LIFU treatment also significantly increased cardiac targeting and circulation time. Further therapeutic evaluations showed that PCM-E2/PFPs + LIFU suppressed cardiac hypertrophy to a greater extent compared to other treatments, revealing high efficiency in cardiac-targeted delivery and effective cardioprotection. Conclusion Our novel theranostic nanoplatform could serve as a potential theranostic vector for cardiac diseases. |
| first_indexed | 2024-04-14T02:07:26Z |
| format | Article |
| id | doaj.art-d49427d79e794b2a9519bb36c89cb355 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-14T02:07:26Z |
| publishDate | 2018-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-d49427d79e794b2a9519bb36c89cb3552022-12-22T02:18:39ZengBMCJournal of Nanobiotechnology1477-31552018-03-0116111410.1186/s12951-018-0360-3Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophyXueli Zhao0Wen Luo1Jing Hu2Lei Zuo3Jing Wang4Rui Hu5Bo Wang6Lei Xu7Jing Li8Meng Wu9Pan Li10Liwen Liu11Department of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Stomatology, PLA Army General HospitalDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityDepartment of Ultrasound, Zhongnan Hospital of Wuhan UniversitySecond Affiliated Hospital of Chongqing Medical University & Chongqing Key Laboratory of Ultrasound Molecular ImagingDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical UniversityAbstract Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system. Furthermore, although 17β-estradiol (E2) is a potential anti-hypertrophic drug, it has severe non-specific adverse effects in various organs. Therefore, we have developed cardiomyocyte-targeted theranostic nanoprobes to achieve concurrent targeted imaging and treatment of cardiac hypertrophy. Results We had successfully synthesized E2-loaded, primary cardiomyocyte (PCM) specific peptide-conjugated nanoprobes with perfluorocarbon (PFP) as a core (PCM-E2/PFPs) and demonstrated their stability and homogeneity. In vitro and in vivo studies confirmed that when exposed to low-intensity focused ultrasound (LIFU), these versatile PCM-E2/PFPs can be used as an amplifiable imaging contrast agent. Furthermore, the significantly accelerated release of E2 enhanced the therapeutic efficacy of the drug and prevented systemic side effects. PCM-E2/PFPs + LIFU treatment also significantly increased cardiac targeting and circulation time. Further therapeutic evaluations showed that PCM-E2/PFPs + LIFU suppressed cardiac hypertrophy to a greater extent compared to other treatments, revealing high efficiency in cardiac-targeted delivery and effective cardioprotection. Conclusion Our novel theranostic nanoplatform could serve as a potential theranostic vector for cardiac diseases.http://link.springer.com/article/10.1186/s12951-018-0360-3Theranostic nanoprobesLow-intensity focused ultrasoundCardiac targetingCardiac hypertrophy17β-estradiol |
| spellingShingle | Xueli Zhao Wen Luo Jing Hu Lei Zuo Jing Wang Rui Hu Bo Wang Lei Xu Jing Li Meng Wu Pan Li Liwen Liu Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy Journal of Nanobiotechnology Theranostic nanoprobes Low-intensity focused ultrasound Cardiac targeting Cardiac hypertrophy 17β-estradiol |
| title | Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| title_full | Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| title_fullStr | Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| title_full_unstemmed | Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| title_short | Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| title_sort | cardiomyocyte targeted and 17β estradiol loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy |
| topic | Theranostic nanoprobes Low-intensity focused ultrasound Cardiac targeting Cardiac hypertrophy 17β-estradiol |
| url | http://link.springer.com/article/10.1186/s12951-018-0360-3 |
| work_keys_str_mv | AT xuelizhao cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT wenluo cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT jinghu cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT leizuo cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT jingwang cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT ruihu cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT bowang cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT leixu cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT jingli cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT mengwu cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT panli cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy AT liwenliu cardiomyocytetargetedand17bestradiolloadedacousticnanoprobesasatheranosticplatformforcardiachypertrophy |